An interventional study of Individual delivery of anti-disinformation messaging and Community delivery of anti-disinformation messaging in Disinformation, Menthol Cigarettes and Flavored Cigars, sponsored by Rutgers, The State University of New Jersey. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Basic science
Our study tests a multi-level anti- disinformation message (ADM) campaign on knowledge and beliefs about menthol cigarette and flavored cigar policies in Black adults.
This study uses a prospective, randomized factorial trial design to evaluate delivery of anti-disinformation messaging (ADM) on Black adults' receptivity to flavored tobacco policies, beliefs about the tobacco industry, and beliefs about menthol cigarettes and flavored cigars. Eligible, consenting participants will complete the baseline survey, providing sociodemographic information and baseline measures of study outcomes. Participants will then be randomized, stratified by study site (Atlanta, GA or Birmingham, AL), in a 1:1 ratio within the survey platform to either the individually-delivered ADM intervention (Intervention-I) or control condition. Participants in the Intervention-I condition will receive their first exposure to the ADM intervention at the end of baseline survey. At follow-up assessments (3-months, 6-months, 9-months, 12-months), all participants will complete study measures and at 3-, 6-, and 9-month follow-up assessments, Intervention-I participants will be exposed to the ADM intervention at the end of the survey. Six months after our first enrollment in the trial, Atlanta will receive the community-delivered ADM intervention (Intervention-C), while Birmingham serves as the control community. Community partners in Atlanta, our Intervention Community, will disseminate our ADM intervention messages through their community networks for 12 months, overlapping at least six months with the delivery of the individual-level intervention (Intervention-I) in our enrolled participants. Upon completion of the final assessment (12-month follow-up), all participants will be exposed to the ADM intervention within the survey platform and asked to complete measures on perceived message effectiveness and credibility of the study messages.
Rutgers, The State University of New Jersey is the lead sponsor of 506 studies on the registry; 131 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 31 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: Individual delivery of anti-disinformation messaging · Behavioral: Community delivery of anti-disinformation messaging
Behavioral: Community delivery of anti-disinformation messaging
Behavioral: Individual delivery of anti-disinformation messaging
Participants in this condition will be exposed to anti-disinformation messages (ADM) designed to increase correct beliefs about menthol cigarettes, flavored cigars, the purpose, and limits of flavored tobacco policies. The delayed intervention control condition in this study will receive the ADM intervention after outcome measures are collected at the last assessment.
Our community-level campaign will distribute our ADM messages to our Intervention Community via social media, print ads and posters, radio ads, and community events. These messages will be delivered over 1 year, with monthly delivery activities led by EAB members in the Intervention Community.
Proportion of participants with specific tobacco industry beliefs
Beliefs items address tobacco industry behaviors, including funding Black community organizations, paying Black lobbyists to oppose public health policies, and targeting Black and African American communities with menthol cigarette and flavored cigar marketing.
Time frame: 3, 6, 9, 12 months
Knowledge about menthol cigarettes and flavored cigars
Items address prevalence of menthol cigarette and flavored cigar use in Black and African Americans and role of menthol/flavors in tobacco initiation, progression, and cessation.
Time frame: 3, 6, 9, 12 months
Knowledge of flavored tobacco policies
Items address the public health purpose and limits of flavored tobacco policies.
Time frame: 3, 6, 9, 12 months
Intention to support flavored tobacco policies
Items address plans to support local, state, and federal policies regarding flavored tobacco products.
Time frame: 3, 6, 9, 12 months
Plan to share: Yes — Deidentified survey responses from participants enrolled in the clinical trial.
Supporting information: Study protocol
Time frame: IPD and supporting information will be available approximately 12 months following the end of data collection or publication of the main study outcomes.
Access criteria: Study data will be deposited in the NAHDAP data repository hosted at the ICPSR and will be available to the research community in perpetuity. Datasets underlying methodological publications will be shared at or prior to initial publication date.
Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Oct 23, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rutgers, The State University of New Jersey →